[1]杨 俊,李璐阳,李浩铭,等.肝动脉化疗栓塞联合靶向及免疫治疗对中晚期肝细胞癌的疗效[J].介入放射学杂志,2025,34(04):398-402.[doi:10.3969/j.issn.1008-794X.2025.04.011]
　YANG Jun,LI Luyang,LI Haoming,et al.Efficacy of transarterial chemoembolization combined with targeted therapy and immunotherapy in treating advanced hepatocellular carcinoma[J].J Intervent Med,2025,34(04):398-402.[doi:10.3969/j.issn.1008-794X.2025.04.011]
点击复制

肝动脉化疗栓塞联合靶向及免疫治疗对中晚期肝细胞癌的疗效()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年04
页码:
398-402
栏目:
临床研究
出版日期:
2025-04-23

文章信息/Info

Title:
Efficacy of transarterial chemoembolization combined with targeted therapy and immunotherapy in treating advanced hepatocellular carcinoma
文章编号:
1008-794X(2025)-004-0398-05
作者:
杨 俊;  李璐阳;  李浩铭;  夏 添;  张 涛;  蒲 猛;  马英博;  张书涵
100142 北京 中国医科大学空军特色医学中心研究生培养基地(杨 俊、李璐阳、李浩铭); 河北北方学院研究生院(夏 添); 空军军医大学空军特色医学中心肝胆外科(张 涛、蒲 猛、马英博、张书涵、刘承利)
Author(s):
YANG Jun; LI Luyang; LI Haoming; XIA Tian; ZHANG Tao; PU Meng; MA Yingbo; ZHANG Shuhan; LIU Chengli.
Postgraduate Training Base of Air Force Medical Center,China Medical University,Beijing 100142,China
关键词:
肝细胞癌;  肝动脉化疗栓塞;  卡瑞利珠单抗;  仑伐替尼
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2025.04.011
文献标志码:
B
摘要:
目的 探讨肝动脉化疗栓塞(TACE)与靶向药物以及免疫检查点抑制剂联合治疗对中晚期肝细胞癌(HCC)患者的疗效及影响因素。方法 纳入2016年1月至2022年12月空军特色医学中心收治的中晚期HCC患者60例,其中TACE联合靶向药物及免疫检查点抑制剂(TACE-L-P)治疗30例,TACE联合靶向单药(TACE-L)治疗30例。比较两组患者的无进展生存期(PFS)、总生存期(OS)、疾病控制率(DCR)和客观缓解率(ORR)。结果 TACE-L组和TACE-L-P的mPFS分别为7个月和10个月(P=0.011),mOS分别为15.5个月和29个月(P=0.014)。Child-Pugh B级(HR=3.89,95%CI:1.27～11.94,P=0.018)、BCLC C期(HR=2.83,95%CI:1.32～6.03,P=0.007)是OS的独立危险因素,微波消融(HR=0.21,95%CI:0.07～0.63,P=0.005)和TACE-L-P(HR=0.09,95%CI:0.03～0.3,P=0.001)是OS的独立保护因素。此外,胆红素(HR=1.03,95%CI:1～1.06,P=0.032)和GGT(HR=1.01,95%CI:1～1.01,P=0.002)水平升高是疾病进展的独立危险因素,TACE-L-P(HR=0.27,95%CI:0.09～0.79,P=0.017)是疾病进展的独立保护性因素。TACE-L-P组的ORR和DCR均高于TACE-L组,分别为43.4% 比 13.3%和63.4% 比23.3%,差异均有统计学意义(均P<0.05)。结论 TACE-L-P治疗晚期HCC的效果比TACE-L更好。

参考文献/References:

[1] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华外科杂志,2022,16:81-96.
[2]Zhao Y,Zhang YN,Wang KT,et al.Lenvatinib for hepatocellular carcinoma:From preclinical mechanisms to anti-cancer therapy[J].Biochim Biophys Acta Rev Cancer,2020,1874:188391.
[3]Qin S,Bi F,Gu S,et al.Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma:a randomized,open-label,parallel-controlled phase Ⅱ-Ⅲ trial[J].J Clin Oncol,2021,39:3002-3011.
[4]Kudo M,Finn RS,Qin SK,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,391:1163-1173.
[5]Sanmamed MF,Chen LP.A paradigm shift in cancer immunotherapy:from enhancement to normalization[J].Cell,2018,175:313-326.
[6]Yau T,Park JW,Finn RS,et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459):a randomised,multicentre,open-label,phase 3 trial[J].Lancet Oncol,2022,23:77-90.
[7]张利捷,梁 斌.免疫检查点阻断与肝癌化疗栓塞[J].介入放射学杂志,2020,29:419-422.
[8]Finn RS,Qin SK,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382:1894-1905.
[9]Cheng AL,Qin S,Ikeda M,et al.Updated efficacy and safety data from IMbrave150:Atezolizumab plus bevacizumab vs.sorafenib for unresectable hepatocellular carcinoma[J].J Hepatol,2022,76:862-873.
[10]Zhang F,Wang Y,Chen G,et al.Growing human hepatocellular tumors undergo a global metabolic reprogramming[J].Cancers(Basel),2021,13:1980.
[11]Kudo M,Finn RS,Edeline JLN,et al.Updated efficacy and safety of KEYNOTE-224:a phase Ⅱ study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J].Eur J Cancer(1965),2022,167:1-12.
[12]Xue R,Zhang Q,Cao Q,et al.Liver tumour immune microenvironment subtypes and neutrophil heterogeneity[J].Nature,2022,612:141-147.
[13]Chang X,Lu X,Guo J,et al.Interventional therapy combined with immune checkpoint inhibitors:Emerging opportunities for cancer treatment in the era of immunotherapy[J].Cancer Treat Rev,2019,74:49-60.
[14]Montasser A,Beaufrere A,Cauchy F,et al.Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma[J].Histopathology,2021,79:36-46.
[15]王 曦,冯 苏,李 红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32:90-93.
[16]Chen YX,Zhang JX,Zhou CG,et al.Comparison of the efficacy and safety of transarterial chemoembolization with or without lenvatinib for unresectable hepatocellular carcinoma:a retrospective propensity Score-Matched analysis[J].J Hepatocell Carcinoma,2022,9:685-694.
[17]Cai M,Huang W,Huang J,et al.Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma:a retrospective cohort study[J].Front Immunol,2022,13:848387.
[18]Duan X,Wang M,Han X,et al.Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice[J].Cell Cycle,2020,19:3595-3607.
[19]Lee CH,Han K,Kim DH,et al.Repeatedly elevated γ-glutamyltransferase levels are associated with an increased incidence of digestive cancers:a population-based cohort study[J].World J Gastroenterol,2021,27:176-188.
(收稿日期:2024-04-18)
(本文编辑:新 宇)

相似文献/References:

[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
　GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(04):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
　SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(04):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
　CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(04):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
　WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(04):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
　WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(04):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[8]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[9]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].J Intervent Med,2012,(04):348.
[10]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
　ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(04):185.

备注/Memo

备注/Memo:
通信作者: 刘承利 E-mail:liuchengli_beijing@163.com
更新日期/Last Update: 2025-04-25